- Home
- AOMR vs ALXO Comparison
AOMR vs ALXO Comparison
Compare AOMR & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AOMR | ALXO |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.5M | 205.9M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AOMR | ALXO |
|---|---|---|
| Price | $7.28 | $1.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $10.55 | $4.60 |
| AVG Volume (30 Days) | 120.5K | ★ 930.4K |
| Earning Date | 11-05-2026 | 11-06-2026 |
| Dividend Yield | ★ 17.53% | N/A |
| EPS Growth | ★ 53.85 | 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.34 | $1.05 |
| 52 Week High | $9.60 | $2.66 |
Technical Indicators
Market Signals| Indicator | AOMR | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 26.38 | 29.67 |
| Support Level | N/A | $1.37 |
| Resistance Level | $9.24 | $1.56 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 2.63 | 12.32 |
Price Performance
Historical ComparisonAbout AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in first and second lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation, across interest rate and credit cycles. The company operates in a single operating segment, which is to acquire, invest in, and finance mortgage-related assets.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.